In this webinar, Douglas Marchuk and Viviana Gradinaru will discuss how scientists can overcome physiological barriers preventing gene therapies from reaching the brain.
Two independent groups suggest the suite of recent unexplained hepatitis cases may stem from coinfection with an adeno-associated virus and a helper adeno- or herpesvirus, a duo which may be especially virulent in children with a particular genetic variant.
Canines treated with an adeno-associated viral (AAV) vector showed evidence that the therapeutic DNA held within the virus can integrate into the host genome, risking the activation of oncogenes.